A.Vogel presents the latest clinical trials on Respiratory tract infections (RTI's)

Each winter, colds and flus put millions of people out of commission. With these dreaded annual infections at our doorstep, Canadians are once again seeking the best option to prevent, treat and beat the inevitable seasonal bugs lurking on every doorknob, in every public bathroom and on every train or bus grab rail on their commutes to school or work.

The results from clinical trials released this May could serve as an answer to this global dilemma.

A.Vogel’s Echinaforce® products have a steady history of clinically proven science backing the efficacy of the product line.

Lead researcher, Professor Sebastian Johnston, Imperial College London, said: “This is the first time we have evidence that Echinacea not only reduces recurrent RTIs but also complications arising out of these infections.”

Dr. Peter Fisher, from the Royal London Hospital for Integrated Medicine stated that, “Neuraminidase inhibitors such as Oseltamivir are the current ‘gold standard’ for flu treatment, but they have significant limitations and side effects. Despite different modes of action, we found Echinaforce Hot Drink to be as effective as the golden standard but with a better safety profile.”